ATTR-CM

BridgeBio's ATTR-CM med Attruby gains traction, crushes analysts' early expectations
Fierce Pharma
Wed, 04/30/25 - 11:09 am
BridgeBio
Attruby
ATTR-CM
Alnylam drug gets long-awaited FDA approval in deadly heart disease
BioPharma Dive
Thu, 03/20/25 - 10:05 pm
Alnylam
Amvuttra
Pfizer
Bridge Bio
FDA
ATTR-CM
Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space
BioSpace
Wed, 03/19/25 - 11:08 pm
Alnylam
ATTR-CM
Pfizer
Bridge Bio
vutrisiran
Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race
First Word Pharma
Tue, 11/26/24 - 11:04 am
Alnylam
FDA
RNAi
vutrisiran
ATTR-CM
Intellia’s gene editing therapy shows early potential in rare heart condition
Clinical Trials Arena
Mon, 11/18/24 - 11:30 am
Intellia
gene editing
NTLA-2001
AHA
ATTR-CM
Pfizer's ATTR heart disease drug needs hefty discount, says ICER draft report. What about Alnylam's Amvuttra?
Fierce Pharma
Fri, 07/19/24 - 11:36 am
Pfizer
tafamidis
ATTR-CM
ICER
drug pricing
BridgeBio Builds on Positive Phase III Data for Acoramidis in ATTR-CM
BioSpace
Thu, 05/30/24 - 11:30 am
BridgeBio Pharma
acoramidis
clinical trials
ATTR-CM
Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace
Fierce Pharma
Mon, 04/22/24 - 06:01 pm
Alnylam
Pfizer
Amvuttra
ATTR-CM
tafamidis
AstraZeneca's phase 3 heart disease trial hits, teeing up Pfizer showdown in Japan
Fierce Biotech
Fri, 02/2/24 - 11:53 am
AstraZeneca
Pfizer
acoramidis
Japan
clinical trials
cardiomyopathy
ATTR-CM
Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts
Fierce Pharma
Mon, 09/18/23 - 08:01 pm
Pfizer
BridgeBio
Alnylam
FDA
clinical trials
ATTR-CM
physicians
tafamidis
Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease
Fierce Pharma
Thu, 09/14/23 - 09:59 am
Alnylam
FDA
Onpattro
ATTR-CM
FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting
BioSpace
Tue, 09/12/23 - 07:06 pm
Alnylam
FDA
ATTR-CM
Onpattro
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Yahoo/GlobeNewswire
Sun, 08/27/23 - 04:28 pm
Bridge Bio
clinical trials
acoramidis
ATTR
ATTR-CM
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Wed, 06/28/23 - 11:44 am
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
Why BridgeBio Pharma Stock Is Plunging Today
Motley Fool
Thu, 06/15/23 - 06:56 pm
BridgeBio
clinical trials
acoramidis
ATTR-CM
Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst
Fierce Pharma
Mon, 10/3/22 - 11:41 pm
Alnylam
Onpattro
Pfizer
ATTR-CM
AstraZeneca and Neurimmune to develop investigational human monoclonal antibody NI006
Biopharma Reporter
Mon, 01/10/22 - 11:43 am
Alexion
AstraZeneca
Neurimmune
NI006
ATTR-CM
Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel
Fierce Biotech
Tue, 02/18/20 - 08:30 pm
Europe
Pfizer
transthyretin amyloidosis
ATTR-CM
Vyndaqel
Pfizer's heart med Vyndaqel off and running thanks to diagnosis push: execs
Fierce Pharma
Tue, 01/28/20 - 11:34 pm
Pfizer
Vyndaqel
ATTR-CM

Pages